Cargando…

The fate of camptothecin glycoconjugate: report of a clinical hold during a phase II study of BAY 56-3722 (formerly BAY 38-3441), in patients with recurrent or metastatic colorectal cancer resistant/refractory to irinotecan

Introduction BAY 56-3722 (formerly BAY 38-3441) is a glycoconjugated campthotecin, which was considered an attractive drug to assess in colorectal cancer (CRC). Patient and methods Phase II study design evaluating the antitumor activity of BAY 56-3722 IV 320 mg/m(2) daily for 3 days every 3 weeks in...

Descripción completa

Detalles Bibliográficos
Autores principales: Slingerland, Marije, Gelderblom, Hans
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3348469/
https://www.ncbi.nlm.nih.gov/pubmed/21547368
http://dx.doi.org/10.1007/s10637-011-9679-4
_version_ 1782232388554719232
author Slingerland, Marije
Gelderblom, Hans
author_facet Slingerland, Marije
Gelderblom, Hans
author_sort Slingerland, Marije
collection PubMed
description Introduction BAY 56-3722 (formerly BAY 38-3441) is a glycoconjugated campthotecin, which was considered an attractive drug to assess in colorectal cancer (CRC). Patient and methods Phase II study design evaluating the antitumor activity of BAY 56-3722 IV 320 mg/m(2) daily for 3 days every 3 weeks in patients with recurrent or metastatic inoperable CRC resistant to irinotecan. Results Twenty-four patients received the study treatment. Triggered by adverse events in two other studies with this compound the study was put on a clinical hold while the safety data were reviewed for the entire program. After the review Bayer decided to withdraw BAY 56-3722 from all clinical investigations. Discussion We felt it was our obligation to share this interrupted phase II study for two reasons: to report the fate of camptothecin glycoconjugate and to report the unique situation of a clinical hold during a phase II study.
format Online
Article
Text
id pubmed-3348469
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-33484692012-05-30 The fate of camptothecin glycoconjugate: report of a clinical hold during a phase II study of BAY 56-3722 (formerly BAY 38-3441), in patients with recurrent or metastatic colorectal cancer resistant/refractory to irinotecan Slingerland, Marije Gelderblom, Hans Invest New Drugs Phase II Studies Introduction BAY 56-3722 (formerly BAY 38-3441) is a glycoconjugated campthotecin, which was considered an attractive drug to assess in colorectal cancer (CRC). Patient and methods Phase II study design evaluating the antitumor activity of BAY 56-3722 IV 320 mg/m(2) daily for 3 days every 3 weeks in patients with recurrent or metastatic inoperable CRC resistant to irinotecan. Results Twenty-four patients received the study treatment. Triggered by adverse events in two other studies with this compound the study was put on a clinical hold while the safety data were reviewed for the entire program. After the review Bayer decided to withdraw BAY 56-3722 from all clinical investigations. Discussion We felt it was our obligation to share this interrupted phase II study for two reasons: to report the fate of camptothecin glycoconjugate and to report the unique situation of a clinical hold during a phase II study. Springer US 2011-05-06 2012 /pmc/articles/PMC3348469/ /pubmed/21547368 http://dx.doi.org/10.1007/s10637-011-9679-4 Text en © The Author(s) 2011 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
spellingShingle Phase II Studies
Slingerland, Marije
Gelderblom, Hans
The fate of camptothecin glycoconjugate: report of a clinical hold during a phase II study of BAY 56-3722 (formerly BAY 38-3441), in patients with recurrent or metastatic colorectal cancer resistant/refractory to irinotecan
title The fate of camptothecin glycoconjugate: report of a clinical hold during a phase II study of BAY 56-3722 (formerly BAY 38-3441), in patients with recurrent or metastatic colorectal cancer resistant/refractory to irinotecan
title_full The fate of camptothecin glycoconjugate: report of a clinical hold during a phase II study of BAY 56-3722 (formerly BAY 38-3441), in patients with recurrent or metastatic colorectal cancer resistant/refractory to irinotecan
title_fullStr The fate of camptothecin glycoconjugate: report of a clinical hold during a phase II study of BAY 56-3722 (formerly BAY 38-3441), in patients with recurrent or metastatic colorectal cancer resistant/refractory to irinotecan
title_full_unstemmed The fate of camptothecin glycoconjugate: report of a clinical hold during a phase II study of BAY 56-3722 (formerly BAY 38-3441), in patients with recurrent or metastatic colorectal cancer resistant/refractory to irinotecan
title_short The fate of camptothecin glycoconjugate: report of a clinical hold during a phase II study of BAY 56-3722 (formerly BAY 38-3441), in patients with recurrent or metastatic colorectal cancer resistant/refractory to irinotecan
title_sort fate of camptothecin glycoconjugate: report of a clinical hold during a phase ii study of bay 56-3722 (formerly bay 38-3441), in patients with recurrent or metastatic colorectal cancer resistant/refractory to irinotecan
topic Phase II Studies
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3348469/
https://www.ncbi.nlm.nih.gov/pubmed/21547368
http://dx.doi.org/10.1007/s10637-011-9679-4
work_keys_str_mv AT slingerlandmarije thefateofcamptothecinglycoconjugatereportofaclinicalholdduringaphaseiistudyofbay563722formerlybay383441inpatientswithrecurrentormetastaticcolorectalcancerresistantrefractorytoirinotecan
AT gelderblomhans thefateofcamptothecinglycoconjugatereportofaclinicalholdduringaphaseiistudyofbay563722formerlybay383441inpatientswithrecurrentormetastaticcolorectalcancerresistantrefractorytoirinotecan
AT slingerlandmarije fateofcamptothecinglycoconjugatereportofaclinicalholdduringaphaseiistudyofbay563722formerlybay383441inpatientswithrecurrentormetastaticcolorectalcancerresistantrefractorytoirinotecan
AT gelderblomhans fateofcamptothecinglycoconjugatereportofaclinicalholdduringaphaseiistudyofbay563722formerlybay383441inpatientswithrecurrentormetastaticcolorectalcancerresistantrefractorytoirinotecan